Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Polypharmacology in Precision Oncology: Current Applications and Future ProspectsPractical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia[Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib]Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureRelative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsBCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib ResistanceABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesThe Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsInduction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.Is imatinib still the best choice as first-line oral TKI.Using 2(nd) generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia.Navigating the road toward optimal initial therapy for chronic myeloid leukemia.Evolution of therapies for chronic myelogenous leukemia.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.Update on emerging treatments for chronic myeloid leukemia.Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cellsLong-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialBCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment.Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage.Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia
P2860
Q26738514-ED07981B-8497-47E6-9C1B-F8B9EB4F3A4EQ30242015-D14241D6-E3C4-4558-B7BC-72CEF6093383Q30846907-9D7E540D-F886-46F7-8396-56893D31E2F4Q34417824-437AC0E8-18EC-4C49-9EF5-7F56EADCF19DQ34522789-DA891668-4AE7-4A64-97FB-F0AA8CE6BA72Q34539293-015C6CC4-51ED-44BA-B7D0-0950835E3BA4Q34894883-99520087-16B3-4E1A-B30B-F0823058C51FQ35596200-1E735DD6-E200-4D62-B476-C0238CD290C1Q35873909-83BF1267-E0F8-43EE-B9BE-49936A56B248Q36026747-80F0356F-CB34-415A-8AA4-AC318E3FE377Q36088825-DEA9EC57-984C-4593-AD5D-6C520A0323FAQ36106559-A9DBFE36-79CE-461B-920B-5BAC60C6D364Q36547224-989D245A-AD85-4E4A-9D7E-A1007389FDACQ37026032-BB03FDE8-7005-46FC-A440-D7F09590A78DQ37509428-ED63097C-1933-4084-BB8A-DBE48FBD3711Q37589123-66BE8A93-9668-4853-8207-8E124F13A0B9Q37654034-91452707-BF49-4DAA-87CC-CCA31520C781Q37654040-832F88AD-6131-4F4A-8EE5-3FB2D7C7C734Q37831034-5D7F71C3-D357-4B83-85E4-139359441C3FQ37966915-C62FD840-BF97-4742-B99F-2046A943EA46Q38139571-A56C98B4-CD25-4720-AD4D-545C8C28C773Q38187115-F6E583AF-295C-4570-BD32-CA1F02965053Q38397515-8CF143E3-63EB-44A9-B48D-A1F514C0D223Q38771802-234854C5-83E7-4D7E-A937-71B48B4969DEQ40807968-9D7C0419-5AC7-4D39-8496-29D9ED844F01Q41980844-949D8290-00DA-42FA-8248-BDBB8A6A6C83Q47149685-132FF279-B58C-4C00-98B8-3ACEC51B3A13Q47269765-E1DB1F77-F0EF-4717-87B5-549A0B1A0A1BQ47870805-BE7EAE71-764F-43AB-9F7D-4FC340886859Q49833785-21194244-9EA6-40EF-BAD8-E9BC2F6CBB51Q49887919-E43E5D03-9F21-4085-BB5F-5F797B57CAB1Q50784710-6E9459CA-B166-4834-A0A7-509594B7648DQ52641581-4A21AD48-C4C2-490E-9640-0D892E03EA09Q53081885-29BD90EE-264E-4966-ADAB-87EDE81481C0Q53670654-E168ECB2-CB3A-41C8-8F46-3524F4A2EBA3Q58124858-8CA3F8BB-CC63-4DDA-BE53-CA5121D719FA
P2860
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nilotinib is associated with a ...... oid leukemia in chronic phase.
@en
Nilotinib is associated with a ...... oid leukemia in chronic phase.
@nl
type
label
Nilotinib is associated with a ...... oid leukemia in chronic phase.
@en
Nilotinib is associated with a ...... oid leukemia in chronic phase.
@nl
prefLabel
Nilotinib is associated with a ...... oid leukemia in chronic phase.
@en
Nilotinib is associated with a ...... oid leukemia in chronic phase.
@nl
P2093
P2860
P50
P921
P1433
P1476
Nilotinib is associated with a ...... oid leukemia in chronic phase.
@en
P2093
Albert Hoenekopp
Carmino De Souza
Dong-Wook Kim
Gabriel Etienne
Matt E Kalaycio
Mineo Kurokawa
Timothy P Hughes
Xiaolin Fan
Yaping Shou
P2860
P304
P356
10.1182/BLOOD-2012-04-423418
P407
P577
2013-03-15T00:00:00Z